Stanford BMT-CT ASTCT Abstracts 2023: Oral Abstracts
1 Circulating Tumor DNA for Disease Characterization and Response Prediction in Myeloma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy
Friday, February 17, 2023
8:45 AM
World Center Marriott - Cypress 3
Hitomi Hosoya, MD PhD1, Mia Carleton2, Kailee Tanaka2, Brian Sworder, MD, PhD2, Vanna Hovanky1, George E Duran2, Tian Y Zhang, MD, PhD3, Michael Khodadoust, MD, PhD2, David B. Miklos, MD, PhD1, Sally Arai, MD1, David Iberri3, Michaela Liedtke, MD3, Surbhi Sidana, MD1 and David Kurtz, MD, PhD2, (1)Division of BMT and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (2)Department of Medicine, Division of Oncology, Stanford University, Stanford, CA, (3)Department of Medicine, Division of Hematology, Stanford University, Stanford, CA
https://tandem.confex.com/tandem/2023/meetingapp.cgi/Paper/21917
2 CD22 CAR T Cell Therapy Induces Durable Remissions in Patients with Large B Cell Lymphoma Who Relapse after CD19 CAR T Cell Therapy
Friday, February 17, 2023
9:00 AM
World Center Marriott - Cypress 3
Matthew J. Frank, MD, PhD1, Bita Sahaf, PhD2, John Baird, MD3, Shabnum Patel, PhD4, Juliana Craig, BA3, Maria Iglesias5, Emma Crawford, BS3, Jean S. Oak, MD, PhD6, Sheren F. Younes, MD, PhD6, Yasodha Natkunam, MD, PhD6, Hrishikesh K. Srinagesh, MD, MSCR3, Jay Spiegel, MD3, Zachary Ehlinger, MS4, Harshini Chinnasamy, MS4, Warren D. Reynolds, BS4, Emily Egeler, PhD4, Sally Arai, MD7, Laura Johnston, MD7, Robert Lowsky, MD7, Robert S. Negrin, MD8, Andrew R. Rezvani, MD7, Parveen Shiraz, MD9, Surbhi Sidana, MD7, Wen-Kai Weng, MD, PhD7, Saurabh Dahiya, MD10, Melody Smith, MD11, Liora Michal Schultz, MD12, Sneha Ramakrishna, MD4, Kara L Davis, D.O.4, Steven Feldman, PhD4, Crystal Mackall, M.D.13, Lori Muffly, MD, MS14 and David B. Miklos, MD, PhD7, (1)Division of BMT and Cellular Therapy, Stanford University, Stanford, CA, (2)Stanford University School of Medicine, Cancer Correlative Science Unit, Stanford Cancer Institute, Stanford, CA, (3)Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, (4)Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford, CA, (5)Stanford University School of Medicine, Stanford, CA, (6)Department of Pathology, Stanford University, Stanford, CA, (7)Division of BMT and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (8)Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, (9)Department of Medicine, Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (10)BMT-CT, Stanford University, Stanford, CA, (11)Stanford University, Stanford, CA, (12)Department of Pediatrics, Bass Center for Childhood Cancer and Blood Disorders, Stanford University School of Medicine, Stanford, CA, (13)Department of Pediatrics, Bass Center for Childhood Cancer and Blood Disorders, Stanford University School of Medicine, Stanford, CA, (14)Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA
https://tandem.confex.com/tandem/2023/meetingapp.cgi/Paper/22151
7 Trajectory of NGS MRD-Detected Clonotypes throughout the First Year Following Allogeneic Hematopoietic Cell Transplantation in Adult Acute Lymphoblastic Leukemia
Emily C. Liang, MD1, Simone E. Dekker, MD, PhD2, Jean M.G. Sabile, MD2, Stefan Torelli, MD3, Amy Zhang, MPH4, Katharine Miller, PhD4, Parveen Shiraz, MD5, Brandon Hayes-Lattin, MD6, Jessica T. Leonard, MD6 and Lori Muffly, MD, MS7, (1)Department of Medicine, University of Washington, Seattle, WA, (2)Department of Medicine, Oregon Health & Science University, Portland, OR, (3)Department of Medicine, Stanford University School of Medicine, Stanford, CA, (4)Department of Medicine, Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, CA, (5)Department of Medicine, Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (6)Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR, (7)Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA
https://tandem.confex.com/tandem/2023/meetingapp.cgi/Paper/20850
12 Ultra-Sensitive Next-Generation Sequencing Establishes the Prognostic Value of Very Low MRD in Adults with Acute Lymphoblastic Leukemia Undergoing Hematopoietic Cell Transplantation
Jean M.G. Sabile, MD1, Simone E. Dekker, MD, PhD1, Emily C. Liang, MD2, Stefan Torelli, MD3, Amy Zhang, MPH4, Katharine Miller, PhD4, Parveen Shiraz, MD5, Brandon Hayes-Lattin, MD6, Jessica T. Leonard, MD6 and Lori Muffly, MD, MS7, (1)Department of Medicine, Oregon Health & Science University, Portland, OR, (2)Department of Medicine, University of Washington, Seattle, WA, (3)Department of Medicine, Stanford University School of Medicine, Stanford, CA, (4)Department of Medicine, Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, CA, (5)Department of Medicine, Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (6)Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR, (7)Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA
https://tandem.confex.com/tandem/2023/meetingapp.cgi/Paper/21640
14 Immune Phenotypic Quantification of Axicabtagene Ciloleucel and Brexucabtagene Autoleucel Demonstrates Lymphoma Histology Specific Differences in CAR19 Expansion and Toxicity.
Mark P. Hamilton, MD, PhD1, Cesar Gentille, MD1, Alain Mina, MD2, Zinaida Good, PhD1, John Tamaresis, Ph.D3, Zachary Ehlinger, MS4, Shriya Syal, MS5, Brian Sworder, MD, PhD6, Joseph Schroers-Martin, MD7, Ying Lu, PhD3, Lori Muffly, MD, MS8, Robert S. Negrin, MD9, Sally Arai, MD10, Laura Johnston10, Robert Lowsky, MD10, Everett H. Meyer, MD, PhD8, Andrew R. Rezvani, MD10, Judith A. Shizuru, MD, PhD10, Wen-Kai Weng, MD, PhD10, Parveen Shiraz, MD11, Surbhi Sidana, MD10, Sushma Bharadwaj, MD4, Melody Smith, MD12, Saurabh Dahiya, MD13, Bita Sahaf, PhD14, David M. Kurtz, MD, PhD15, Crystal Mackall, M.D.16, Ash A. Alizadeh15, Matthew J. Frank, MD, PhD17 and David B. Miklos, MD, PhD10, (1)Center for Cancer Cell Therapy, Stanford University, Stanford, CA, (2)Stanford, Stanford, CA, (3)Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, (4)Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford, CA, (5)The Center for Cancer Cell Therapy, Stanford University, Stanford, CA, (6)Department of Medicine, Division of Oncology, Stanford University, Stanford, CA, (7)Hematology and Oncology, Stanford, Stanford, CA, (8)Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (9)Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, (10)Division of BMT and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (11)Department of Medicine, Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (12)Department of Medicine, Weill Cornell Medical College, New York, NY, (13)Transplantation & Cellular Therapy Program, Division of Hematology/Oncology, Department of Internal Medicine, Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, (14)Stanford University School of Medicine, Cancer Correlative Science Unit, Stanford Cancer Institute, Stanford, CA, (15)Hematology and Oncology, Stanford University, Stanford, CA, (16)Department of Pediatrics, Bass Center for Childhood Cancer and Blood Disorders, Stanford University School of Medicine, Stanford, CA, (17)Stanford University, Palo Alto, CA
https://tandem.confex.com/tandem/2023/meetingapp.cgi/Paper/21766
16 Interim Analysis of a Phase II Study of Administered Fresh Bispecific Anti-CD20/Anti-CD19 CAR T-Cell Therapy - Zamtocabtagene Autoleucel (zamto-cel) for Relapsed/Refractory (R/R) DLBCL (DALY II USA NCT04792489)
Nirav N. Shah, MD1, Richard T Maziarz, MD2, Caron A. Jacobson, MD, MMSc3, Monalisa Ghosh4, Iris Isufi, MD5, Matthew L. Ulrickson, MD6, Miguel-Angel Perales, MD7, Matthew Lunning8, Dr. Nancy Maureen Hardy, MD9, Anna Wijatyk, MD10, Marek Ancukiewicz11, Mrs. Madhavi Nallewar11, Kimberly C. Coleman, BSN, RN11, Bethany Prudner12, Esther Eromosele11, Remi Kaleta13 and David B. Miklos, MD, PhD14, (1)Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI, (2)Adult Blood and Marrow Stem Cell Transplant Program, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, (3)Harvard Medical School, Boston, MA, (4)University of Michigan Hospital, Ann Arbor, MI, (5)Hematology, Yale University School of Medicine, New Haven, CT, (6)Division of Cancer Medicine, Banner MD Anderson Cancer Center, Gilbert, AZ, (7)Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, (8)Hematology/Oncology Division, University of Nebraska Medical Center, Omaha, NE, (9)Experimental Transplantation and Immunology, NCI, Bethesda, MD, (10)Miltenyi Biomedicine, Lexington, MA, (11)Miltenyi Biomedicine Inc., Waltham, MA, (12)Miltenyi biomedicine Inc., waltham, MA, (13)miltenyi biomedicine Inc., Waltham, MA, (14)Division of BMT and Cellular Therapy, Stanford University School of Medicine, Stanford, CA
https://tandem.confex.com/tandem/2023/meetingapp.cgi/Paper/21672
18 A Phase 1 Study of ADI-001: Anti-CD20 CAR-Engineered Allogeneic Gamma Delta1 (γδ) T Cells in Adults with B-Cell Malignancies
Sattva S. Neelapu, MD1, Don A. Stevens, MD2, Mehdi Hamadani, MD3, Matthew J. Frank, MD, PhD4, Houston Holmes, MD5, Aya Jacobovits, PHD6, John Hinkle, PHD7, Jackie Kennedy-Wilde, MS6, Ori Maller, PHD8, Bayarmagnai Weinstein, MD PHD6, Francesco Galimi, MD PHD6, Rose K Lai, MD6 and David B. Miklos, MD, PhD9, (1)Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, (2)Norton Cancer Institute, Louisville, KY, (3)BMT & Cellular Therapy Program, Medical College of Wisconsin, Milwakee, WI, (4)Division of BMT and Cellular Therapy, Stanford University, Stanford, CA, (5)Texas Oncology, Dallas, TX, (6)Adicet Therapeutics, Redwood City, CA, (7)Adicet Therapeutics, redwood city, CA, (8)Adiect Therapeutics, Redwood City, CA, (9)Division of BMT and Cellular Therapy, Stanford University School of Medicine, Stanford, CA
https://tandem.confex.com/tandem/2023/meetingapp.cgi/Paper/21031
30 Orca-T, a High-Precision Cell Therapy, for the Treatment of Hematologic Malignancies in Patients with 7/8 Mismatch Donors
Anna Pavlova, MD, PhD1, Robert Lowsky, MD1, Lori Muffly, MD, MS1, Nathaniel B. Fernhoff, PhD2, James Scott McClellan, MD, PhD2, Robert S. Negrin, MD1 and Everett H. Meyer, MD, PhD1, (1)Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (2)Orca Bio, Menlo Park, CA
https://tandem.confex.com/tandem/2023/meetingapp.cgi/Paper/22174
33 Orca-Q Demonstrates Favorable GvHD-and-Relapse-Free Survival with Haploidentical Donors without Post-Transplant Cyclophosphamide
Samer A. Srour, MB ChB, MS1, Amandeep Salhotra, MD2, Robert Lowsky, MD3, Rasmus T Hoeg, MD4, Ayman Saad, MB/BCH5, Anna Pavlova, MD, PhD3, Edmund K. Waller, MD, PhD6, Mwe Mwe Chao, MD7, James Scott McClellan, MD, PhD7, Nathaniel B. Fernhoff, PhD7, Everett H. Meyer, MD, PhD3 and Mehrdad Abedi, MD4, (1)Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, (2)Department of Hematology/HCT, City of Hope National Medical Center, Duarte, CA, (3)Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (4)Comprehensive Cancer Center, University of California, Davis, Sacramento, CA, (5)Comprehensive Cancer Center, The Ohio State University, Columbus, OH, (6)Bone Marrow and Stem Cell Transplant Center, Emory University Winship Cancer Institute, Atlanta, GA, (7)Orca Bio, Menlo Park, CA
https://tandem.confex.com/tandem/2023/meetingapp.cgi/Paper/22196
39 Checkpoint Inhibitors Based Salvage Regimens Lead to Higher Survival in Relapsed Refractory Classic Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant.
Sanjal H Desai1, Michael A Spinner, MD2, Kevin David, MD3, Veronika Bachanova4, Gaurav Goyal, MD5, Brad S. Kahl, MD6, Kathleen Dorritie, MD7, Jacques Azzi8, Vaishalee P Kenkre, MD9, Sally Arai, MD10, Cheryl Chang, BA2, Brendon Fusco, MD3, Nuttavut Sumransub4, Haris Hactic, MD11, Raya Saba, MD, MSCI12, Uroosa Ibrahim, MD13, Elyse I Harris, MD14, Matthew J Maurer15, Harsh Shah, DO16, Nina Wagner-Johnston, MD17, Deepa Jagadeesh, MD, MPH18, Victor Orellana-Noia19, Catherine Diefenbach, MD20, Siddharth Iyengar, MD21, KC Rappazzo, MD22, Rahul Mishra, MD23, Yun Choi, MD24, Grzegorz S Nowakowski, MD25, Ranjana Advani26 and Ivana N Micallef25, (1)Sanjal H Desai, minneapolis, MN, (2)Division of Oncology, Department of Medicine, Stanford University Medical Center, Stanford, CA, (3)Department of Hematology & Medical Oncology, Rutgers Cancer Institute of New Jersey, Newark, NJ, (4)Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, (5)University of Alabama at Birmingham, Birmingham, AL, (6)Washington University School of Medicine, St. Louis, MO, (7)UPMC Hillman Cancer Center, Pittsburgh, PA, (8)Division of Hematology & Medical Oncology, Icahn School of Medicine Mount Sinai, New York, NY, (9)Bone Marrow Transplant Program, Carbone Cancer Center, University of Wisconsin - Madison, Madison, WI, (10)Division of BMT and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (11)O’Neal Comprehensive Cancer Center, Birmingham, AL, (12)Division of Hematology and Oncology, Washington University in St Louis, St. Louis, MO, (13)Bone Marrow Transplantation and Cellular Therapy, The Mount Sinai Hospital, New York, NY, (14)Department of Hematology, University of Wisconsin, Madison, WI, (15)Department of Health Sciences Research, Mayo Clinic, Rochester, MN, (16)Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, (17)Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, (18)Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, (19)Division of Hematology and Medical Oncology, Winship Cancer Institute, Atlanta, GA, (20)Perlmutter Cancer Center, NYU Grossman Medical School, New York, NY, (21)Division of Hematology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, (22)Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, (23)Cleveland Clinic Foundation, Cleveland, OH, (24)Perlmutter Cancer Center, NYU Langone Medical School, New York, NY, (25)Division of Hematology, Mayo Clinic, Rochester, MN, (26)Stanford Cancer Center, Stanford, CA
https://tandem.confex.com/tandem/2023/meetingapp.cgi/Paper/21152
42 - Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) with Renal Impairment: Real World Experience
Surbhi Sidana, MD1, Lauren Peres, MPH, PhD2, Hamza Hashmi, MD3, Hitomi Hosoya, MD PhD1, Christopher Ferreri4, Shebli Atrash, MD, MS5, Jack Khouri, MD6, Peter M. Voorhees, MD5, Danai Dima7, Gary Lee Simmons, DO8, Nilesh Kalariya, PhD, RN, AGPCNP-BC9, Vanna Hovanky1, Sushma Bharadwaj, MD10, Sally Arai, MD1, David B. Miklos, MD, PhD1, Charlotte Wagner11, James Davis, PharmD12, Douglas Sborov, MD13, Taiga Nishihori, MD14, Melissa Alsina, MD14, Frederick L. Locke, MD14, Rebecca Gonzalez, PharmD, BCOP14, Mehmet H. Kocoglu, MD15, Aishwarya Sannareddy, MBBS16, Aimaz Afrough, MD16, Joseph P. McGuirk, DO17, Leyla Shune, MD18, Krina K. Patel, MD, MSc19 and Doris K Hansen, MD14, (1)Division of BMT and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (2)Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, (3)Medical University of South Carolina, Charleston, SC, (4)The University of Texas MD Anderson Cancer Center, Houston, TX, (5)Hematologic Oncology and Blood Disorders, Atrium Health, Levine Cancer Institute, Charlotte, NC, (6)Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, (7)Cleveland Clinic Foundation, Cleveland, OH, (8)Bone Marrow Transplant, VCU Massey Cancer Center, Richmond, VA, (9)Lymphoma/Myeloma, M D Anderson Cancer Center, Houston, TX, (10)Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford, CA, (11)The University of Utah Huntsman Cancer Institute,, Salt Lake City, UT, (12)Pharmacy, Medical University of South Carolina, Charleston, SC, (13)University of Utah School of Medicine, Salt Lake City, UT, (14)Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, (15)Transplantation & Cellular Therapy Program, Division of Hematology/Oncology, Department of Internal Medicine, Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, (16)Division of Hematologic Malignancies and Cellular Therapy, Department of Internal Medicine, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, (17)Division of Hematologic Malignancies and Cellular Therapeutics, Kansas University Medical Center, Kansas City, KS, (18)Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, (19)Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
https://tandem.confex.com/tandem/2023/meetingapp.cgi/Paper/22114
48 Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref Non-Hodgkin Lymphoma.
Sushma Bharadwaj, MD1, Mark P. Hamilton, MD, PhD2, Bita Sahaf, PhD3, John Tamaresis, Ph.D4, Theresa M. Latchford, RN, MS, CNS, BMTCN, AOCNS5, Sally Arai, MD6, Laura Johnston, MD6, Robert Lowsky, MD6, Robert S. Negrin, MD7, Andrew R. Rezvani, MD6, Judith A. Shizuru, MD, PhD6, Everett H. Meyer, MD, PhD8, Parveen Shiraz, MD9, Surbhi Sidana, MD6, Melody Smith10, Wen-Kai Weng, MD, PhD6, Lori Muffly, MD, MS8, Crystal Mackall, M.D.11, Matthew J. Frank, MD, PhD12, David B. Miklos, MD, PhD6 and Saurabh Dahiya, MD13, (1)Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford, CA, (2)Center for Cancer Cell Therapy, Stanford University, Stanford, CA, (3)Stanford University School of Medicine, Cancer Correlative Science Unit, Stanford Cancer Institute, Stanford, CA, (4)Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, (5)Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, (6)Division of BMT and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (7)Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, (8)Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (9)Department of Medicine, Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (10)Medicine, Division of BMT-CT, Stanford, Stanford, CA, (11)Department of Pediatrics, Bass Center for Childhood Cancer and Blood Disorders, Stanford University School of Medicine, Stanford, CA, (12)Stanford University, Palo Alto, CA, (13)BMT-CT, Stanford University, Stanford, CA
https://tandem.confex.com/tandem/2023/meetingapp.cgi/Paper/21959
54 Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity
Caspian Oliai, MD, MS1, Rasmus T Hoeg, MD2, Anna Pavlova, MD, PhD3, Arpita Gandhi, MD4, Lori Muffly, MD, MS3, Rohtesh S. Mehta, MD, MPH, MS5, Samer A. Srour, MB ChB, MS5, Edmund K. Waller, MD, PhD6, Robert Lowsky, MD3, Sagar S. Patel, MD7, Bhagirathbhai Dholaria, M.B.B.S.8, Carlos R. Bachier, MD9, Jeremy Pantin, MD10, Amandeep Salhotra, MD11, Joseph P. McGuirk, DO12, Nathaniel B. Fernhoff, PhD13, James Scott McClellan, MD, PhD13, Mehrdad Abedi, MD2, Robert S. Negrin, MD3 and Everett H. Meyer, MD, PhD3, (1)UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, (2)Comprehensive Cancer Center, University of California, Davis, Sacramento, CA, (3)Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (4)Oregon Health Sciences University, Portland, OR, (5)Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, (6)Bone Marrow and Stem Cell Transplant Center, Emory University Winship Cancer Institute, Atlanta, GA, (7)Blood and Marrow Transplant Program, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, (8)Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN, (9)Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio, TX, (10)Sarah Cannon Transplant and Cellular Therapy Program at TriStar Centennial Medical Center, Nashville, TN, (11)Department of Hematology/HCT, City of Hope National Medical Center, Duarte, CA, (12)Division of Hematologic Malignancies and Cellular Therapeutics, Kansas University Medical Center, Kansas City, KS, (13)Orca Bio, Menlo Park, CA
https://tandem.confex.com/tandem/2023/meetingapp.cgi/Paper/21868
59 Subanalysis from Phase 1 Study of JSP191, an Anti-CD117 Monoclonal Antibody, in Combination with Low Dose Irradiation and Fludarabine Conditioning, Shows Durable Remissions in Older Adults with Acute Myleoid Leukemia in Complete Remission Undergoing Allogeneic Hematopoietic Cell Transplantation
Lori Muffly, MD, MS1, Catherine J. Lee, MD2, Arpita Gandhi, MD3, Ankur Varma, MD, MPH4, Bart L. Scott, MD5, Hye-Sook Kwon, PhD6, Minyoung Youn, PhD6, Chikako Yanagiba, MS6, Jeyakavitha Arulprakasam, MS6, Anne Le, BS6, Judith A. Shizuru, MD, PhD7, Wendy W. Pang, MD, PhD6 and Andrew S. Artz, MD8, (1)Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (2)Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, (3)Oregon Health Sciences University, Portland, OR, (4)Division of Hematology, Oncology and Cellular Therapy, Rush University Medical Center, Chicago, IL, (5)Fred Hutchinson Cancer Research Center, Seattle, WA, (6)Jasper Therapeutics, Inc., Redwood City, CA, (7)Division of BMT and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (8)Department of Hematology/HCT, City of Hope National Medical Center, Duarte, CA
https://tandem.confex.com/tandem/2023/meetingapp.cgi/Paper/21934
86 Evaluation of Clinical Outcomes and Healthcare Resource Use of Outpatient Allogeneic Stem Cell Transplant in Older Adults with AML/MDS, Using JSP191, an Anti-CD117 Monoclonal Antibody, in Combination with Low Dose Irradiation and Fludarabine Conditioning – a Single Center Analysis
Lori Muffly, MD, MS1, Gary Goldstein, BA2, Aaron Miller, BA3, Anne Le, BS3, David Ku, MD3 and Wendy W. Pang, MD, PhD3, (1)Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (2)Blood & Marrow Transplant Program, Stanford Medicine, Palo Alto, CA, (3)Jasper Therapeutics, Inc., Redwood City, CA
https://tandem.confex.com/tandem/2023/meetingapp.cgi/Paper/22152
Stanford BMT-CT ASTCT Abstracts 2023: Poster Abstracts
128 Pre-Transplant Measurable Residual Disease By Next-Generation Sequencing Is a Better Predictor of Relapse Compared to BCR-ABL PCR in Adult Patients with Ph+ Acute Lymphoblastic Leukemia
Simone E. Dekker, MD, PhD1, Jean M.G. Sabile, MD1, Emily C. Liang, MD2, Brandon A DaSilva, MD3, Stefan Torelli, MD3, Andy Kaempf, MS4, Jeong Youn Lim, PhD4, Parveen Shiraz, MD5, Brandon Hayes-Lattin, MD6, Lori Muffly, MD, MS7 and Jessica T. Leonard, MD6, (1)Department of Medicine, Oregon Health & Science University, Portland, OR, (2)Department of Medicine, University of Washington, Seattle, WA, (3)Department of Medicine, Stanford University School of Medicine, Stanford, CA, (4)Biostatistics Shared Resource, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, (5)Department of Medicine, Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (6)Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR, (7)Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA
https://tandem.confex.com/tandem/2023/meetingapp.cgi/Paper/22097
211 Initial Results from Stanford Children’s Fanconi Anemia Clinical Trial Using JSP191 Antibody Conditioning and TCRαβ+ T-Cell/CD19+ B-Cell Depleted Grafts
Rajni Agarwal, MD1, Alice Bertaina, MD, PhD2, Rofida Nofal, MD, MS3, Gopin Saini, MBBS4, Nivedita Kunte, BHMS5, Sushmita Sen, MS6, Yan Yi Chan3, Hana Willner6, Matthias Felber, MD6,7, Mark R. Krampf, MS8,9, Maite Van Hentenryck, MD10, Emily Walck, BA11, Amelia Scheck3, Supawat Thongthip, PhD3, Aaron C. Logan, MD, PhD, MPhil12, Kirstin Dougall, MBA10, Alisha Bouge, MS6, Jaap Jan Boelens, MD, PhD13, Janel Renee Long-Boyle, PharmD, PhD14, Robertson Parkman, MD2, Irving L Weissman, MD15, Judith A. Shizuru, MD, PhD16, Wendy W. Pang, MD, PhD17, Maria Grazia Roncarolo, MD18, Matthew H. Porteus, MD, PhD3 and Agnieszka Czechowicz, MD, PhD1,19,20, (1)Lucile Packard Children's Hospital, Palo Alto, CA, (2)Department of Pediatrics - Division of Hematology, Oncology, Stem Cell Transplantation, and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, (3)Division of Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University Medical Center, Stanford, CA, (4)Center for Definitive and Curative Medicine, Stanford University School of Medicine, Stanford, CA, (5)Pediatric Stem Cell & Gene Therapy Clinical Trial office, Stanford University School of Medicine, Palo Alto, CA, (6)Pediatrics, Stanford University School of Medicine, Stanford, CA, (7)Department of Immunology, Hematology, Oncology and SCT, University Children's Hospital Zurich Switzerland, Zurich, Switzerland, (8)Pediatrics-Stem Cell Transplantation, Stanford University, Stanford, CA, (9)Dept. of Medicine, Div. of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, (10)Stanford University School of Medicine, Stanford, CA, (11)Pediatrics Division of Stem Cell Transplantation and Regenerative Medicine, Stanford Medicine, Stanford, CA, (12)Div. Hematology, BMT, & Cellular Therapy, University of California, San Francisco, San Francisco, CA, (13)MSK Kids, Transplantation and Cellular Therapy, Memorial Sloan Kettering Cancer Center, New York, NY, (14)Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA, (15)Institute for Stem Cell Biology and Regenerative Medicine, Stanford University Medical Center, Stanford, CA, (16)Division of BMT and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (17)Jasper Therapeutics, Inc., Redwood City, CA, (18)Department of Pediatrics/ Division of Hematology, Oncology, Stem Cell Transplantation, and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, (19)Center for Definitive and Curative Medicine, Stanford University, Stanford, CA, (20)Department of Pediatrics, Division of Hematology, Oncology, Stem Cell Transplantation, and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA
https://tandem.confex.com/tandem/2023/meetingapp.cgi/Paper/20757
239 CD39 Delineates Chimeric Antigen Receptor T Regulatory Cell Populations with Different Cytotoxic and Immunoregulatory Potential Against Monocytes and Pancreatic Islet Beta Cells
Xiangni Wu1, Pin-I Chen1, Shiva Pathak1, Robert L Whitener2, Vy Nguyen2, Bettina P. Iliopolou1, Kauhleen R. Mangayan1, Kent P. Jensen1,3, Seung K. Kim, MD, PhD2,4 and Everett H. Meyer, MD, PhD3,4,5, (1)Division of Blood and Bone Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, (2)Department of Developmental Biology, Stanford University School of Medicine, Stanford, CA, (3)Cellular Immune Tolerance Program, Stanford Department of Medicine, Stanford, CA, (4)Stanford Diabetes Research Center, Stanford University School of Medicine, Stanford, CA, (5)Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA
https://tandem.confex.com/tandem/2023/meetingapp.cgi/Paper/21863
274 Early Results of a Phase I Study of CAR-T Cells + NKTR-255 (PEG-IL-15) in Adults with R/R ALL
Clayton Jackson, MD1, Parveen Shiraz, MD1, Maria Iglesias2, Emily Egeler, PhD3, Bita Sahaf, PhD4, Sally Arai, MD5, Sushma Bharadwaj, MD3, Laura Johnston, MD5, Robert Lowsky, MD5, Everett H. Meyer, MD, PhD6, Robert S. Negrin, MD7, Andrew R. Rezvani, MD5, Wen-Kai Weng, MD, PhD5, Judith A. Shizuru, MD, PhD5, Mario Q. Marcondes, MD, PhD8, Mary A. Tagliaferri, MD8, Surbhi Sidana, MD5, Matthew J. Frank, MD, PhD9, Melody Smith10, Steven Feldman, PhD3, David B. Miklos, MD, PhD5, Crystal Mackall, M.D.11, Shriya Syal, MS12, Sunita Patil, MS2, Warren D. Reynolds, BS3 and Lori Muffly, MD, MS6, (1)Department of Medicine, Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (2)Stanford University School of Medicine, Stanford, CA, (3)Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford, CA, (4)Stanford University School of Medicine, Cancer Correlative Science Unit, Stanford Cancer Institute, Stanford, CA, (5)Division of BMT and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (6)Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (7)Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, (8)Nektar Therapeutics, San Francisco, CA, (9)Stanford University, Palo Alto, CA, (10)Medicine, Division of BMT-CT, Stanford, Stanford, CA, (11)Department of Pediatrics, Bass Center for Childhood Cancer and Blood Disorders, Stanford University School of Medicine, Stanford, CA, (12)The Center for Cancer Cell Therapy, Stanford University, Stanford, CA
https://tandem.confex.com/tandem/2023/meetingapp.cgi/Paper/22020
351 Immune Biomarkers Associated with Chronic Gvhd in Phase 1 Study of JSP191, an Anti-CD117 Monoclonal Antibody, in Combination with Low Dose Irradiation and Fludarabine Conditioning in Older Adults with MDS/AML Undergoing Allogeneic HCT
Minyoung Youn, PhD1, Lori Muffly, MD, MS2, Andrew S. Artz, MD3, Catherine J. Lee, MD4, Arpita Gandhi, MD5, Ankur Varma, MD, MPH6, Bart L. Scott, MD7, Chikako Yanagiba, MS1, Rajiv L Tiwari, PhD8, Jeyakavitha Arulprakasam, MS1, Anne Le, BS1, Judith A. Shizuru, MD, PhD9, Hye-Sook Kwon, PhD1 and Wendy W. Pang, MD, PhD1, (1)Jasper Therapeutics, Inc., Redwood City, CA, (2)Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (3)Department of Hematology/HCT, City of Hope National Medical Center, Duarte, CA, (4)Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, (5)Oregon Health Sciences University, Portland, OR, (6)Division of Hematology, Oncology and Cellular Therapy, Rush University Medical Center, Chicago, IL, (7)Fred Hutchinson Cancer Research Center, Seattle, WA, (8)Jasper Therapeutics, Redwood City, CA, (9)Division of BMT and Cellular Therapy, Stanford University School of Medicine, Stanford, CA
https://tandem.confex.com/tandem/2023/meetingapp.cgi/Paper/21949
444 Stool Screening for Sars-Cov-2 RNA for COVID-19 in Patients Undergoing Hematopoietic Cell Transplantation, Cellular Therapy, and Induction Chemotherapy
Christopher J. Severyn, MD, PhD, Pediatrics, Heme/Onc/SCTRM, Stanford University School of Medicine, Palo Alto, CA, Aravind Natarajan, PhD, Genetics and Medicine (Hematology, Blood and Marrow Transplantation), Stanford University, Stanford, CA, Danica T. Schmidtke, BS, Microbiology and Immunology, Stanford University, Stanford, CA, Erin F Brooks, BS, MS, Medicine (Hematology, Blood and Marrow Transplantation), Stanford University, Stanford, CA, Haley Hedlin, PhD, Quantitative Sciences Unit, Stanford University, Stanford, CA, Inna Kaplan, RN, MSN, Medicine (Blood and Marrow Transplantation and Cellular Therapy), Stanford University, Stanford, CA, Andrew R. Rezvani, MD, Division of BMT and Cellular Therapy, Stanford University School of Medicine, Stanford, CA and Ami S. Bhatt, MD, PhD, Medicine (Hematology and BMT) and Genetics, Stanford University, Stanford, CA
https://tandem.confex.com/tandem/2023/meetingapp.cgi/Paper/21185
469 - A Retrospective Analysis to Identify Barriers in Allogeneic Hematopoietic Stem Cell Transplantation with Ethnically Diverse Population
McAtee, Jennifer1, Zhang, Bing M2, Stanford Medicine-Health Care, Stanford, CA. Department of Pathology, Stanford University School of Medicine, Stanford, CA.
https://tandem.confex.com/tandem/2023/meetingapp.cgi/Paper/22209
496 Outcomes of Subsequent Anti-Lymphoma Therapies in Patients (Pts) with Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel) or Standard of Care (SOC) in the Second-Line (2L) Zuma-7 Study
Armin Ghobadi, MD1, Javier Muñoz, MD, MS, MBA, FACP2, Jason R. Westin, MD, MS, FACP3, Frederick L. Locke, MD4, David B. Miklos, MD, PhD5, Aaron P. Rapoport, MD6, Miguel-Angel Perales, MD7, Patrick M. Reagan, MD8, Joseph P. McGuirk, DO9, Caron A. Jacobson, MD, MMSc10, Marie José Kersten, MD, PhD11, Irit Avivi12, Andrew Peng, MS13, Marco Schupp, MD13, Christina To, MD13 and Olalekan O. Oluwole, MBBS, MPH14, (1)Division of Oncology, Washington University School of Medicine, St. Louis, MO, (2)Banner MD Anderson Cancer Center, Gilbert, AZ, (3)Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, (4)Moffitt Cancer Center, Tampa, FL, (5)Stanford University School of Medicine, Stanford, CA, (6)University of Maryland School of Medicine and Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD, (7)Memorial Sloan-Kettering Cancer Center, New York City, NY, (8)University of Rochester School of Medicine, Rochester, NY, (9)University of Kansas Cancer Center, Kansas City, KS, (10)Dana-Farber Cancer Institute, Boston, MA, (11)Amsterdam UMC, University of Amsterdam, on behalf of HOVON/LLPC, Amsterdam, Netherlands, (12)Tel-Aviv Sourasky (Ichilov) Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, (13)Kite, a Gilead Company, Santa Monica, CA, (14)Vanderbilt University Cancer Center, Nashville, TN
https://tandem.confex.com/tandem/2023/meetingapp.cgi/Paper/20916
504 Outcomes of Hematopoietic Cell Transplantation for Hepatosplenic T-Cell Lymphoma: A US Multicenter Collaborative Study
Muhamad Alhaj Moustafa, MD, MS1, Jeremy L Ramdial, MD2, Athanasios Tsalatsanis, PhD3, Farhad Khimani, MD4, Bhagirathbhai Dholaria, M.B.B.S.5, Leyla Bojanini, MD6, Jasmine Zain, MD7, Dr. N. Nora Bennani, MD8, Zachary Braunstein, MD9, Jonathan E. Brammer, MD10, Prof. Amer Beitinjaneh, MD, MSc, MPH, FACP11, Wen-Kai Weng, MD, PhD12, Ambuj Kumar, MD, MPH13, Mohamed A. Kharfan-Dabaja, MD, MBA1, Hemant Murthy, M.D.1 and Sairah Ahmed, MD2, (1)Division of Hematology and Medical Oncology, & BMT/Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, (2)Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, (3)Division of Evidence Based Medicine and Outcomes Research, Department of Internal Medicine, University of South Florida Morsani College of Medicine, Tampa, FL, (4)Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, (5)Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN, (6)Stanford University School of Medicine, Palo Alto, CA, (7)Hematology/Hematopoietic Cell Transplant, City of Hope National Medical Center, Duarte, CA, (8)Hematology, Mayo Clinic, Rochester, MN, (9)Department of Internal Medicine, Ohio State University Wexner Medical Center, Columbus, OH, (10)Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, (11)Division of Transplantation and Cellular Therapy, University of Miami, FL, (12)Division of BMT and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (13)Program for Comparative Effectiveness Research, University of South Florida, Morsani College of Medicine, Tampa, FL
https://tandem.confex.com/tandem/2023/meetingapp.cgi/Paper/22069
590 Development of Germ Cell Tumor Disease Response Criteria to Standardize Data Management Practices
Laura Johnston and Matthew Firchal, Division of BMT and Cellular Therapy, Stanford University School of Medicine, Stanford, CA
https://tandem.confex.com/tandem/2023/meetingapp.cgi/Paper/22103
ASTCT SCIENTIFIC WORKSHOPS
How I Manage ALL in AYA Patients
Saturday, February 18, 2023
12:00 PM - 1:15 PM
World Center Marriott - Magnolia 12
Lori Muffly, MD, MS, Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA
https://tandem.confex.com/tandem/2023/meetingapp.cgi/Paper/22212
Conditioning with a Naked Antibody: The Target Matters
Thursday, February 16, 2023
8:45 AM - 9:15 AM
World Center Marriott - Cypress 3
Judith A. Shizuru, MD, PhD, Division of BMT and Cellular Therapy, Stanford University School of Medicine, Stanford, CA
https://tandem.confex.com/tandem/2023/meetingapp.cgi/Paper/21210
How to Structure and Lead a Clinical Data Management Team
Wednesday, February 15, 2023
11:50 AM - 12:10 PM
World Center Marriott - Sago
Marin L. Jackson, Department of Medicine, Division of Blood & Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA
https://tandem.confex.com/tandem/2023/meetingapp.cgi/Paper/21404